Atlanta-based Vero Biotech designed Genosyl for inhaled nitric oxide (iNO) delivery. This approval covers the second-generation Genosyl device. The third-generation device — which recently received FDA approval — has not yet been tested with rebreathing anesthesia. The company expects data for this setting available for the newer system in the first quarter of this year.
Get the full story at our sister site, Drug Delivery Business News.